3'-Selenobisalanine" No Further a Mystery
All enrolled patients who gained at the least a person dose of zosuquidar or placebo during induction have been monitored with the occurrence of adverse functions (439 people, 219 on zosuquidar and 210 on placebo). The most typical adverse events had been connected to the duration of extended and sizeable myelosuppression as is anticipated with ind